Is Fusithalmic (fusidic acid) eyedrop suitable for adults with bacterial conjunctivitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fusidic Acid (Fucithalmic) for Bacterial Conjunctivitis in Adults

Yes, fusidic acid 1% viscous eye drops (Fucithalmic) is an appropriate and effective treatment option for adults with mild to moderate bacterial conjunctivitis, offering the advantage of twice-daily dosing compared to more frequent administration required by other topical antibiotics. 1, 2

Treatment Approach for Bacterial Conjunctivitis in Adults

Mild Bacterial Conjunctivitis

  • Mild bacterial conjunctivitis is typically self-limited and resolves spontaneously in immunocompetent adults without treatment. 3, 4
  • However, topical antibacterial therapy provides earlier clinical and microbiological remission during days 2-5 of treatment compared to placebo, with benefits persisting through days 6-10. 3
  • A 5-7 day course of broad-spectrum topical antibiotic is recommended, with the choice based on convenience and cost since no particular antibiotic demonstrates clinical superiority. 3, 4

Fusidic Acid Efficacy and Dosing

  • Fusidic acid 1% viscous drops administered twice daily demonstrates equivalent clinical and bacteriological efficacy to tobramycin 0.3% (dosed 4-6 times daily) and chloramphenicol 0.5% (dosed 6 times daily). 1, 2
  • The carbomer vehicle in Fucithalmic provides prolonged antibiotic concentration in tear fluid, enabling the convenient twice-daily dosing regimen. 2
  • Clinical studies show 87-90% satisfactory response rates with fusidic acid treatment over 7 days. 5

Important Caveats About Fusidic Acid

  • One placebo-controlled trial found no significant difference in 7-day cure rates between fusidic acid and placebo (adjusted risk difference 5.3%, 95% CI -11 to 18), though bacterial eradication was superior with fusidic acid (76% vs 41%). 6
  • In vitro resistance to fusidic acid can be relatively high (46% in one study), though this did not consistently translate to clinical treatment failure. 7
  • All four treatment failures in one comparative study occurred in the fusidic acid group versus none with lomefloxacin. 7
  • Fusidic acid causes more burning sensation compared to fluoroquinolones. 7

Moderate to Severe Bacterial Conjunctivitis

  • For moderate to severe cases characterized by copious purulent discharge, pain, and marked inflammation, obtain conjunctival cultures and Gram staining before initiating treatment. 3, 4
  • Consider methicillin-resistant Staphylococcus aureus (MRSA), which has increasing prevalence in community-acquired infections and nursing home residents. 3, 8
  • Treatment choice should be guided by culture results in severe cases. 3

When to Avoid or Reconsider Fusidic Acid

  • If gonococcal infection is suspected (hyperacute presentation with severe purulent discharge), systemic antibiotics are mandatory in addition to topical therapy. 3, 4
  • Consider alternative antibiotics (fluoroquinolones, aminoglycosides) if MRSA is suspected or confirmed. 3, 8
  • Refer to ophthalmology if visual loss, moderate-to-severe pain, corneal involvement, or lack of response after 3-4 days occurs. 4

Clinical Bottom Line

Fusidic acid is a reasonable first-line option for uncomplicated bacterial conjunctivitis in adults due to its twice-daily convenience and comparable efficacy to other topical antibiotics. However, given the mixed evidence regarding superiority over placebo and potential resistance concerns, fluoroquinolones may be preferred when higher bacterial eradication rates are prioritized or in regions with known fusidic acid resistance patterns. 3, 1, 6

References

Research

Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Conjunctivitis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The treatment of acute infectious conjunctivitis with fusidic acid: a randomised controlled trial.

The British journal of general practice : the journal of the Royal College of General Practitioners, 2005

Guideline

Treatment of Bacterial Conjunctivitis in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.